Tsang T S, Califf R M, Stebbins A L, Lee K L, Cho S, Ross A M, Armstrong P W
Department of Medicine, University of Alberta, Edmonton, Canada.
Am J Cardiol. 1997 May 1;79(9):1232-5. doi: 10.1016/s0002-9149(97)00087-8.
We evaluated allergic reactions in 20,201 patients randomized to the streptokinase arms of The Global Utilization of Streptokinase and t-PA (Tissue Plasminogen Activator) in Occluded Coronary Arteries (GUSTO-I) trial, and tested the hypothesis that patients with streptokinase allergy would exhibit higher mortality. After adjusting for baseline variables and time of death, we found comparable coronary patency, left ventricular function, mortality, and bleeding complications between patients with versus those without streptokinase allergy.
我们评估了20201例随机分配至全球应用链激酶和组织型纤溶酶原激活剂（t-PA）治疗闭塞冠状动脉（GUSTO-I）试验链激酶组患者的过敏反应，并检验了链激酶过敏患者死亡率会更高这一假设。在对基线变量和死亡时间进行校正后，我们发现链激酶过敏患者与无链激酶过敏患者之间的冠状动脉通畅情况、左心室功能、死亡率及出血并发症相当。
